#United States #oncology #Amgen #Thousand Oaks #ESMO2026

Amgen's Engagement with the ESMO 2026 Congress

In an exciting opportunity for investors and healthcare professionals, Amgen (NASDAQ: AMGN) is set to host a webcast coinciding with the prestigious European Society of Medical Oncology (ESMO) Congress 2026. Scheduled for Saturday, October 24, 2026, at 11:30 a.m. PT, the event will feature discussions led by Amgen's key executives, showcasing insights into their oncology portfolio and the latest data being presented at the congress.

Key Speakers and Topics

The webcast will be led by Murdo Gordon, who serves as the Executive Vice President of Global Markets and Policy at Amgen. Joining him will be Jean-Charles Soria, the Senior Vice President of Oncology within Amgen's Global Development division, along with other notable members of Amgen’s management team. Together, they will delve into Amgen’s innovative approaches and advancements in oncology treatments.

This dialogue promises to bring forth valuable insights on the strategies employed by Amgen to tackle some of the most challenging forms of cancer, alongside highlighting clinical data that underscores the efficacy of their therapies. Participants will have the opportunity to gain first-hand knowledge of how Amgen is leveraging biological science and technology in their drug development process.

Accessibility and Participation

The webcast will be accessible to a diverse audience that includes news media representatives, investors, and the general public. This inclusivity reflects Amgen’s commitment to transparency and dialogue in the medical community. Interested parties are encouraged to tune into the live session via Amgen's official website, where details regarding presentation times and access links will be made available.

Furthermore, the webcast will be archived and available for replays for at least 30 days post-event, ensuring that a broader audience can benefit from the discussion even if they are unable to join live.

A Legacy of Innovation

Understanding Amgen’s core mission enhances the significance of their participation at ESMO 2026. Established over 45 years ago in Thousand Oaks, California, Amgen has played a pivotal role in the biotechnology industry. The company focuses on discovering, developing, and delivering innovative medicines aimed at combating serious illnesses, particularly in oncology, inflammatory conditions, rare diseases, and more. Amgen has consistently positioned itself at the forefront of biomedical innovation, integrating genetic research to push the boundaries of existing treatments.

Among the accolades that Amgen has received, it has been honored by renowned publications such as Fast Company and Forbes for both innovation and workplace culture. As a member of the Dow Jones Industrial Average® and the Nasdaq-100 Index®, Amgen continues to lead with a robust pipeline of medical solutions that seek to address major health challenges worldwide.

The upcoming ESMO Congress 2026 is a critical platform for Amgen to showcase not only their advancements in oncology but also their commitment to collaborative engagement with the global medical community. The insights shared during this event can significantly impact investor decisions and healthcare strategies going forward.

For more detailed information on Amgen’s initiatives, visit their official site at Amgen.com and follow their updates on social media platforms including X (formerly Twitter), LinkedIn, Instagram, YouTube, and Threads. Be part of the conversation and witness how Amgen continues to innovate and influence the future of healthcare.